Loading
In six patients, eradicating the stomach bacterium Helicobacter pylori with antibiotics made low-grade gastric lymphoma regress, proving that a cancer could be caused by, and treated through, a chronic infection.
Case series of six patients with primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type and Helicobacter pylori infection treated with antibiotics to eradicate the organism.
In five patients the lymphoma regressed histologically and endoscopically after eradication, supporting the hypothesis that the lymphoma is driven by antigenic stimulation from the infection.
Antibiotic eradication is the first-line treatment for Helicobacter pylori-positive gastric MALT lymphoma, curing most patients without chemotherapy or radiotherapy.
Shares Helicobacter pylori eradication as cancer treatment in gastric MALT lymphoma, Gastric MALT lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares Gastric MALT lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Helicobacter pylori eradication as cancer treatment in gastric MALT lymphoma, Gastric MALT lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares The Lancet, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Gastric MALT lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.